IL229749A0 - Stable formulations of hyaluronan-degrading enzyme - Google Patents

Stable formulations of hyaluronan-degrading enzyme

Info

Publication number
IL229749A0
IL229749A0 IL229749A IL22974913A IL229749A0 IL 229749 A0 IL229749 A0 IL 229749A0 IL 229749 A IL229749 A IL 229749A IL 22974913 A IL22974913 A IL 22974913A IL 229749 A0 IL229749 A0 IL 229749A0
Authority
IL
Israel
Prior art keywords
hyaluronan
degrading enzyme
stable formulations
formulations
stable
Prior art date
Application number
IL229749A
Other languages
English (en)
Hebrew (he)
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halozyme Inc filed Critical Halozyme Inc
Publication of IL229749A0 publication Critical patent/IL229749A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL229749A 2011-06-17 2013-12-02 Stable formulations of hyaluronan-degrading enzyme IL229749A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161520962P 2011-06-17 2011-06-17
PCT/US2012/042816 WO2012174478A2 (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Publications (1)

Publication Number Publication Date
IL229749A0 true IL229749A0 (en) 2014-01-30

Family

ID=46513830

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229749A IL229749A0 (en) 2011-06-17 2013-12-02 Stable formulations of hyaluronan-degrading enzyme

Country Status (13)

Country Link
EP (1) EP2720712B1 (https=)
JP (3) JP2014518216A (https=)
KR (2) KR101874401B1 (https=)
CN (2) CN105797140B (https=)
AU (2) AU2012271359B2 (https=)
BR (1) BR112013032396A2 (https=)
CA (1) CA2839511C (https=)
EA (2) EA201400031A1 (https=)
ES (1) ES2566549T3 (https=)
IL (1) IL229749A0 (https=)
MX (1) MX340172B (https=)
NZ (2) NZ618331A (https=)
WO (1) WO2012174478A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP3130347B1 (en) 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
RU2019128331A (ru) * 2013-02-04 2019-12-16 Санофи Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
WO2015145860A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN104095871A (zh) * 2014-07-10 2014-10-15 青岛蔚蓝生物股份有限公司 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液
EP3169351B1 (en) * 2014-07-16 2020-02-26 New York University Use of hyaluronidase for treatment of muscle stiffness
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN105018457A (zh) * 2015-07-20 2015-11-04 宁波美成生物科技有限公司 虫荧光素酶稳定剂
CN108699120B (zh) * 2015-11-16 2022-05-13 Ubi蛋白公司 用于延长蛋白质半衰期的方法
JP6798030B2 (ja) 2016-09-06 2020-12-09 シンファー ティアン−リー ファーマシューティカル カンパニー リミテッド（ハンツォウ）Ｓｉｎｐｈａｒ Ｔｉａｎ−Ｌｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． （Ｈａｎｇｚｈｏｕ） 皮膚ケアおよび／または創傷治癒促進における松塊抽出物およびその有効成分の使用
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
CN108070532A (zh) * 2016-11-16 2018-05-25 福建力多利生物科技有限公司 一种生产葡萄糖氧化酶的方法
US11510967B2 (en) 2017-09-08 2022-11-29 Eli Lilly And Company Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
CN107918020B (zh) * 2017-11-15 2019-01-01 浙江夸克生物科技有限公司 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒
EP3636752A4 (en) 2018-07-25 2021-04-28 Alteogen, Inc. NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
MY204342A (en) 2019-03-25 2024-08-24 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
CN110592056A (zh) * 2019-09-19 2019-12-20 昆明理工大学 噬菌体裂解酶复合粉剂及其制备方法和应用
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
EP3992285A4 (en) * 2020-01-23 2023-01-25 Alteogen, Inc. NOVEL HYALURONIC HYDROLYZING ENZYME VARIANT WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION CONTAINING IT
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
WO2022141232A1 (zh) * 2020-12-30 2022-07-07 上海宝济药业有限公司 一种重组人透明质酸酶制剂及其应用
EP4424301A4 (en) * 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
CN115820766B (zh) * 2021-12-28 2024-11-12 华熙生物科技股份有限公司 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
AU2023408268A1 (en) * 2022-12-23 2025-07-10 Hanmi Pharm. Co., Ltd. Formulations comprising immune stimulating IL-2 analog conjugates
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
CN117243852A (zh) * 2023-11-01 2023-12-19 华熙生物科技股份有限公司 一种皮肤外用组合物及其用途
CN119074669B (zh) * 2024-06-21 2025-04-18 邢珺月 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0162007A1 (de) * 1984-04-18 1985-11-21 Geriaco AG Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris
EP0250119A3 (en) * 1986-06-20 1990-04-18 Vasocor Atherosclerotic anti-idiotype antibody immunoassay and reagents
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6669663B1 (en) * 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6563022B2 (en) * 1999-07-05 2003-05-13 Toyo Boseki Kabushiki Kaisha Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
AU2001255675B2 (en) * 2000-05-19 2005-04-14 Alcon, Inc. Disulfide derivatives useful for treating allergic diseases
US6902548B1 (en) * 2001-03-19 2005-06-07 Ed Schuler Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments
US20030125234A1 (en) * 2001-12-11 2003-07-03 Middaugh Charles Russell Alteration of protein stability
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
EP1620553A4 (en) * 2003-04-23 2007-01-03 Hexima Ltd INSECT CHYMOTRYPSIN AND INHIBITORS THEREOF
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
AU2005227757C1 (en) * 2004-03-31 2009-08-13 Hexima Ltd Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence
WO2005118799A1 (en) * 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
WO2007047242A2 (en) * 2005-10-14 2007-04-26 Soll David B Ophthalmic surgical irrigating solutions containing hyaluronidase
JP2009512709A (ja) * 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
WO2008016729A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
KR20140130512A (ko) 2008-03-06 2014-11-10 할로자임, 아이엔씨 가용성 히알루로니다아제의 대규모 제조
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN103205407B (zh) 2008-12-09 2016-03-16 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
JP5890516B2 (ja) * 2011-06-17 2016-03-22 ハロザイム インコーポレイテッド ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
EP3130347B1 (en) * 2011-12-30 2019-09-18 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof

Also Published As

Publication number Publication date
WO2012174478A2 (en) 2012-12-20
JP6224802B2 (ja) 2017-11-01
EA201400031A1 (ru) 2014-07-30
KR20140043438A (ko) 2014-04-09
MX340172B (es) 2016-06-28
CA2839511C (en) 2018-07-31
EP2720712B1 (en) 2016-03-02
ES2566549T3 (es) 2016-04-13
EA033472B1 (ru) 2019-10-31
JP2017036313A (ja) 2017-02-16
AU2012271359A1 (en) 2014-01-09
NZ717728A (en) 2016-04-29
MX2013014923A (es) 2014-02-11
JP2017197556A (ja) 2017-11-02
KR101874401B1 (ko) 2018-07-04
WO2012174478A9 (en) 2013-05-30
EP2720712A2 (en) 2014-04-23
CN103974715A (zh) 2014-08-06
JP2014518216A (ja) 2014-07-28
CA2839511A1 (en) 2012-12-20
BR112013032396A2 (pt) 2016-11-22
AU2016202472B2 (en) 2017-02-02
EA201501068A1 (ru) 2016-07-29
WO2012174478A3 (en) 2013-04-11
CN105797140B (zh) 2020-08-11
KR20170116173A (ko) 2017-10-18
NZ618331A (en) 2016-04-29
CN105797140A (zh) 2016-07-27
AU2012271359B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
IL229749A0 (en) Stable formulations of hyaluronan-degrading enzyme
AU2016202472A1 (en) Stable formulations of a hyaluronan-degrading enzyme
EP2756410A4 (en) GEOMIGRATION OF USER STATUS
ZA201403788B (en) Stable pesticidal compositions
GB201110042D0 (en) Growth of cells
EP2705485A4 (en) PLATFORM COLLECTION OF ADVERTISING METHODS
GB201112231D0 (en) Micro-organism
IL229086A0 (en) Distortions of algae
IL229700A0 (en) Dronvir formulations
GB201114725D0 (en) Ophthalmic formulations
GB2512737B (en) Micro-Fermentation of cocoa
IL224192A (en) Compositions of Vitamin 14 – Epi Analogs d
GB2493964B (en) Cultivator
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
GB201110278D0 (en) Formulations
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
HK1191236A (en) Stable formulations of a hyaluronan-degrading enzyme
GB201105360D0 (en) Formulations
GB201111013D0 (en) Formulations
GB201111578D0 (en) Pharmeutical formulations
GB201104049D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201102795D0 (en) Formulations